The Efficacy and Safety of F520 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma (PTCL).

NCT04457830 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

105

Enrollment

INDUSTRY

Sponsor class

Conditions

Peripheral T Cell Lymphoma

Interventions

DRUG: F520

Sponsor

Shandong New Time Pharmaceutical Co., LTD